{
  "event": {
    "ticker": "COGT",
    "company": "Cogent Biosciences, Inc.",
    "drug": "bezuclastinib (CGT9486)",
    "application_type": "NDA",
    "indication": "Bezuclastinib in combination with sunitinib for locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) after prior imatinib (PEAK)",
    "pdufa_date": "2026-11-30"
  },
  "display": {
    "company": "Cogent",
    "drug": "bezuclastinib",
    "indication_en": "GIST",
    "indication_zh": "胃肠道间质瘤"
  },
  "probability_approval": 0.88,
  "confidence": "medium",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "A randomized Phase 3 trial against the active standard of care met its primary endpoint by a wide margin",
      "direction": "+",
      "step": "large",
      "evidence": "PEAK: PFS by blinded independent central review was 16.5 vs 9.2 months, HR 0.50 (95% CI 0.39–0.65, p<0.0001), for bezuclastinib + sunitinib vs sunitinib alone in imatinib-resistant or intolerant GIST. ORR was 46% vs 26%, and the benefit held across KIT-mutation subgroups. Because the comparator is sunitinib alone, the trial directly shows what bezuclastinib adds to the combination. The FDA has previously approved GIST drugs on PFS (e.g. ripretinib).",
      "source": "SEC 8-K 2026-08-10 (Q2 2026 results, EX-99.1); ASCO 2026 abstract 11500 (JCO 44:16_suppl); CancerNetwork PEAK coverage"
    },
    {
      "factor": "Every expedited-review signal is present, and the FDA flagged no review issues at filing",
      "direction": "+",
      "step": "medium",
      "evidence": "Breakthrough Therapy Designation (January 2026) and Real-Time Oncology Review. The NDA was submitted in March 2026 and accepted with priority review in May 2026, with an FDA-assigned PDUFA date of 2026-11-30. In the acceptance release, Cogent said the FDA had no plan to hold an advisory committee and had not identified any potential review issues. No PDUFA extension as of 2026-10-04.",
      "source": "SEC 10-Q for Q2 2026 (filed 2026-08-10); Cogent press release 2026-05-28; Cogent press release 2026-09-15 (restates GIST PDUFA 2026-11-30)"
    },
    {
      "factor": "The combination is more toxic, and overall survival is still immature",
      "direction": "-",
      "step": "small",
      "evidence": "Grade ≥3 treatment-related AEs: 71.6% with the combination vs 52.4% with sunitinib. Discontinuation for treatment-related AEs: 7.4% vs 3.8%. Grade ≥3 ALT/AST elevation: 10.8% vs 1.4% (all resolved; no grade 4; 1.5% discontinued). No treatment-related deaths on the combination. OS has not been reported. The FDA's 2025 draft guidance treats OS as a safety readout, so it may ask for interim OS showing no harm. This is mainly a labeling question rather than a likely cause of a CRL.",
      "source": "Cogent ASCO 2026 press release (BioSpace, 2026-05-30); CancerNetwork; SEC 8-K 2026-08-10 ('Data for overall survival remains immature')"
    },
    {
      "factor": "First commercial product for a small company, made by contract manufacturers including a single-source API supplier",
      "direction": "-",
      "step": "small",
      "evidence": "Cogent has never had an approved product. The tablets use a spray-dried dispersion, a moderately complex formulation. On 2026-09-01 Cogent signed a 5-year commercial supply agreement with Hovione for the dispersion and the tablets. Hovione is an established spray-drying CDMO; its published FDA inspection history (Loures, Cork, New Jersey, Macau) shows no warning letters, and recent inspections were clean. The API manufacturer is not named in filings, so its inspection status cannot be judged. The same CMC package also supports the NonAdvSM NDA (PDUFA 2026-12-30).",
      "source": "SEC 8-K 2026-09-02 (Item 1.01, Hovione supply agreement); Cogent 10-K risk factors (sole-source API and drug product suppliers); Hovione inspections-history page"
    },
    {
      "factor": "The company is behaving as if it expects to launch",
      "direction": "+",
      "step": "small",
      "evidence": "Cogent has hired and onboarded its full field commercial and medical team and signed the commercial supply contract. It reports pro forma cash of $865.9M, enough to fund operations into late 2028, and says pre-approval manufacturing costs will be capitalized after approval. This is consistent with management confidence, but it is not independent evidence about the FDA's decision.",
      "source": "SEC 8-K 2026-08-10 (EX-99.1); SEC 10-Q Q2 2026"
    }
  ],
  "manufacturing_risk": {
    "level": "low",
    "why": "This is an oral small molecule, and the tablets and spray-dried intermediate are made at Hovione, an experienced CDMO with a clean published FDA inspection record. The residual risks are that this is Cogent's first commercial product and that the API comes from a single unnamed supplier whose inspection history cannot be checked. I cannot judge that site, which is the main unquantified uncertainty."
  },
  "what_would_change_my_mind": [
    "A PDUFA extension (major amendment) would by itself only move the date; it would matter more if it followed an FDA request for OS or safety data",
    "Disclosure of interim OS data, especially any trend against the combination",
    "Any FDA 483, OAI classification or import alert at Hovione or at the unnamed API site",
    "A late-cycle meeting disclosure, an advisory committee being scheduled, or a problem in the parallel NonAdvSM review (shared CMC package)"
  ],
  "summary_en": "We put approval of bezuclastinib plus sunitinib for imatinib-pretreated GIST at 88%, above the ~76% base rate for small/mid-cap original applications. The randomized Phase 3 PEAK trial beat the active standard of care decisively (independently reviewed PFS 16.5 vs 9.2 months, HR 0.50, p<0.0001). The review has Breakthrough designation, RTOR and priority review, and the FDA said at filing that it saw no review issues and planned no advisory committee. Against that: the combination is more toxic (grade ≥3 treatment-related AEs 72% vs 52%, with more liver-enzyme rises), overall survival is immature, and this is Cogent's first commercial product, with a single-source API. Confidence is medium.",
  "summary_zh": "我们估计 bezuclastinib 联合舒尼替尼治疗伊马替尼经治 GIST 获批的概率为 88%，高于中小型公司新药约 76% 的基准。随机 III 期 PEAK 研究以明显优势击败现行标准治疗（独立评审无进展生存期 16.5 对 9.2 个月，HR 0.50，p<0.0001）。该申请获得突破性疗法认定、实时肿瘤审评和优先审评，FDA 受理时表示未发现审评问题，也不计划召开专家咨询会。不利因素：联合用药毒性更高（3 级以上治疗相关不良事件 72% 对 52%，肝酶升高更多），总生存期数据尚不成熟，且这是 Cogent 首个商业化产品，原料药为单一来源。把握度中等。",
  "sources": [
    "SEC 10-Q, Cogent Biosciences, quarter ended 2026-06-30 (filed 2026-08-10): GIST NDA submitted March 2026 under RTOR, accepted with Priority Review May 2026, PDUFA 2026-11-30, BTD January 2026 — https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm",
    "SEC 8-K 2026-08-10, EX-99.1 Q2 2026 results (PEAK data, commercial team, cash runway) — https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm",
    "SEC 8-K 2026-09-02, Item 1.01 Commercial Supply Agreement with Hovione — https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/d184156d8k.htm",
    "Cogent press release 2026-05-28, FDA acceptance of GIST NDA with Priority Review (no AdCom planned, no review issues identified) — https://sg.finance.yahoo.com/news/cogent-biosciences-announces-fda-acceptance-120000938.html",
    "Cogent press release 2026-09-15, AdvSM NDA acceptance (restates GIST PDUFA 2026-11-30, NonAdvSM 2026-12-30) — https://www.globenewswire.com/news-release/2026/09/15/3361988/0/en/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-for-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-advsm.html",
    "Cogent ASCO 2026 PEAK press release (safety table, discontinuations) — https://www.biospace.com/press-releases/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-clinical-oncology-asco-annual-meeting",
    "ASCO 2026 abstract 11500, Primary results of the phase 3 PEAK study — https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11500",
    "https://www.cancernetwork.com/view/bezuclastinib-plus-sunitinib-meets-pfs-end-point-in-kit-mutant-gist",
    "https://www.onclive.com/view/fda-grants-priority-review-to-bezuclastinib-plus-sunitinib-for-previously-treated-gist",
    "Hovione FDA inspections history — https://www.hovione.com/products-and-services/supporting-capabilities/quality-and-compliance/quality/inspections-history"
  ],
  "zh": {
    "indication": "Bezuclastinib 联合 sunitinib，用于既往接受过 imatinib 治疗的局部晚期、不可切除或转移性胃肠道间质瘤（GIST）；PEAK 研究",
    "key_factors": [
      {
        "factor": "一项以现行标准治疗为对照的随机 3 期试验以较大优势达到主要终点",
        "evidence": "PEAK：在 imatinib 耐药或不耐受的 GIST 中，bezuclastinib + sunitinib 对比 sunitinib 单药，经盲态独立中心评估的无进展生存期（PFS）为 16.5 个月对 9.2 个月，风险比（HR）0.50（95% CI 0.39–0.65，p<0.0001）。客观缓解率（ORR）为 46% 对 26%，且获益在各 KIT 突变亚组中一致。由于对照组为 sunitinib 单药，该试验直接显示了 bezuclastinib 在联合方案中的增益。FDA 此前曾基于 PFS 批准 GIST 药物（如 ripretinib）。"
      },
      {
        "factor": "所有加快审评信号均已具备，且 FDA 在受理时未指出任何审评问题",
        "evidence": "获得突破性疗法认定（2026 年 1 月）并纳入实时肿瘤审评（RTOR）。新药申请（NDA）于 2026 年 3 月提交，2026 年 5 月获受理并获优先审评，FDA 确定的 PDUFA 目标日期为 2026 年 11 月 30 日。Cogent 在受理公告中称，FDA 不计划召开专家咨询委员会会议，也未发现任何潜在审评问题。截至 2026 年 10 月 4 日，PDUFA 目标日期未延期。"
      },
      {
        "factor": "联合方案毒性更大，且总生存期（OS）数据仍不成熟",
        "evidence": "≥3 级治疗相关不良事件：联合组 71.6%，sunitinib 组 52.4%。因治疗相关不良事件停药：7.4% 对 3.8%。≥3 级 ALT/AST 升高：10.8% 对 1.4%（均已缓解；无 4 级；1.5% 停药）。联合组无治疗相关死亡。OS 尚未报告。FDA 2025 年的指南草案将 OS 视为安全性指标，因此可能要求提供显示无害的 OS 中期数据。这主要是说明书层面的问题，不太可能成为完全回应函（CRL）的原因。"
      },
      {
        "factor": "小型公司的首个商业化产品，由合同生产商（CDMO）生产，其中包括单一来源的原料药（API）供应商",
        "evidence": "Cogent 此前从未有产品获批。该片剂采用喷雾干燥分散体，属于中等复杂度的制剂。2026 年 9 月 1 日，Cogent 与 Hovione 签署了为期 5 年的分散体和片剂商业供应协议。Hovione 是一家成熟的喷雾干燥 CDMO；其公开的 FDA 检查记录（Loures、Cork、新泽西、澳门）显示没有警告信，近期检查结果良好。申报文件未指明 API 生产商，因此无法判断其检查状况。同一化学、生产与控制（CMC）资料包还支持非晚期系统性肥大细胞增多症（NonAdvSM）的 NDA（PDUFA 目标日期为 2026 年 12 月 30 日）。"
      },
      {
        "factor": "公司的行为表明其预期产品将会上市",
        "evidence": "Cogent 已完成全部一线商业及医学事务团队的招聘和入职，并签署了商业供应合同。公司报告备考现金为 8.659 亿美元，足以支持运营至 2028 年底，并表示获批后将把批准前的生产成本资本化。这与管理层的信心相符，但并非关于 FDA 决定的独立证据。"
      }
    ],
    "manufacturing_risk_why": "这是一款口服小分子，片剂及喷雾干燥中间体由经验丰富的 CDMO Hovione 生产，其公开的 FDA 检查记录良好。剩余风险在于这是 Cogent 的首个商业化产品，且 API 来自一家未具名的单一供应商，其检查历史无法核查。我无法判断该场地的情况，这是主要的未量化不确定性。",
    "what_would_change_my_mind": [
      "PDUFA 目标日期延期（重大修改）本身只会推迟日期；若延期发生在 FDA 要求提供 OS 或安全性数据之后，则影响更大",
      "披露 OS 中期数据，尤其是任何不利于联合方案的趋势",
      "Hovione 或该未具名 API 场地收到 FDA 483 表、被列为 OAI 或被列入进口警示",
      "披露后期审评会议情况、安排召开专家咨询委员会会议，或平行进行的 NonAdvSM 审评出现问题（共用 CMC 资料包）"
    ]
  },
  "recorded_at": "2026-10-04T19:58:14+00:00"
}